Endogenous Peptide
From Preproinsulin to Two-Chain Insulin
Endogenous insulin is produced through precursor processing, forms a disulfide-linked mature structure, and acts through regulated secretion and receptor signaling.
Educational content only. Not medical advice.
Insulin begins as preproinsulin
The human INS gene encodes preproinsulin, which enters the endoplasmic reticulum through an N-terminal signal peptide. Signal-peptide removal yields proinsulin, where the future A and B chains are connected by C-peptide. Folding and disulfide formation establish the mature architecture before proteolytic processing. The final insulin molecule contains A and B chains linked by disulfide bonds; it is not a single continuous mature chain.
Secretory granules complete processing and storage
Prohormone convertases and carboxypeptidase activity remove C-peptide and basic connecting residues in the secretory pathway. Insulin and C-peptide are packaged and released together, while incompletely processed proinsulin-related forms can also appear. Granule maturation, beta-cell stimulation, calcium, and membrane fusion control release. Assays for insulin, proinsulin, and C-peptide therefore report related but distinct analytes.
The insulin receptor is a receptor tyrosine kinase
Insulin binding changes the preassembled receptor and promotes kinase activity and phosphorylation. Adaptor proteins connect the receptor with PI3K-AKT, MAP kinase, and other networks. Cellular response depends on receptor abundance, nutrient state, feedback, phosphatases, trafficking, and tissue-specific machinery. A signaling measurement in one engineered cell system does not represent the full integrated endocrine response.
Endogenous insulin and engineered analogues require separate records
Manufactured insulins may change residues, formulation, association state, or other attributes to alter absorption or duration. Those products should be identified by exact sequence and product evidence rather than folded into native insulin biology. This page focuses on the endogenous precursor and receptor system and contains no administration, amount, protocol, or treatment guidance.
Even when a product retains the human insulin sequence, formulation can change oligomerization and release behavior. Molecular sequence, product composition, and exposure profile are separate identity layers and should not be merged in an evidence summary.
Evidence limits
- Cellular signaling varies with tissue, metabolic context, model, and measurement time.
- Endogenous processing biology should not be generalized to every manufactured analogue or formulation.
- This page gives no treatment, amount, administration, or personal-use guidance.
Sources and further reading
These sources ground the definitions and evidence boundaries on this page. A citation is a route for verification, not an endorsement of a product or personal use.
UniProt Consortium
INS - Insulin - Homo sapiens
Reviewed human precursor entry with signal peptide, propeptide, insulin chains, disulfides, sequence, and function.
Open sourceNational Center for Biotechnology Information
INS Insulin Gene
Official human gene record linking transcripts, protein products, genomic context, and curated references.
Open sourceCommon questions
Is mature insulin one continuous peptide chain?
No. Mature insulin has A and B chains connected by disulfide bonds after C-peptide is removed from proinsulin.
Are insulin and C-peptide released together?
They arise from the same proinsulin processing event and are co-secreted, though their later clearance differs.
Is the insulin receptor a GPCR?
No. It is a receptor tyrosine kinase with a distinct signaling architecture.
Continue with context
Continue in the evidence workspace
Explore the complete PeptideSchool research workspace to organize sources, compare evidence layers, and follow related peptide science. Premium tools remain educational and do not provide individualized medical guidance.